Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients

Haruka Shinke, Satohiro Masuda, Yousuke Togashi, Yasuaki Ikemi, Aiko Ozawa, Tomoko Sato, Young Hak Kim, Michiaki Mishima, Takaharu Ichimura, Joseph V. Bonventre, Kazuo Matsubara

研究成果: ジャーナルへの寄稿記事

36 引用 (Scopus)

抄録

Purpose: Acute kidney injury (AKI) is a common and serious adverse effect of cisplatin-based chemotherapy. However, traditional markers of kidney function, such as serum creatinine, are suboptimal, because they are not sensitive measures of proximal tubular injury. We aimed to determine whether the new urinary biomarkers such as kidney injury molecule-1 (KIM-1), monocyte chemotactic protein-1 (MCP-1), and neutrophil gelatinase-associated lipocalin (NGAL) could detect cisplatin-induced AKI in lung cancer patients in comparison with the conventional urinary proteins such as N-acetyl-β-d-glucosaminidase (NAG) and β2-microglobulin. Methods: We measured KIM-1, MCP-1, NGAL, NAG, and β2-microglobulin concentrations in urine samples from 11 lung cancer patients, which were collected the day before cisplatin administration and on days 3, 7, and 14. Subsequently, we evaluated these biomarkers by comparing their concentrations in 30 AKI positive (+) and 12 AKI negative (-) samples and performing receiver operating characteristic (ROC) curve analyses. Results: The urinary levels normalized with urine creatinine of KIM-1 and MCP-1, but not NGAL, NAG, and β2-microglobulin in AKI (+) samples were significantly higher than those in AKI (-) samples. In addition, ROC curve analyses revealed that KIM-1 and MCP-1, but not NGAL, could detect AKI with high accuracy (area under the curve [AUC] = 0.858, 0.850, and 0.608, respectively). The combination of KIM-1 and MCP-1 outperformed either biomarker alone (AUC = 0.871). Conclusions: Urinary KIM-1 and MCP-1, either alone or in combination, may represent biomarkers of cisplatin-induced AKI in lung cancer patients.

元の言語英語
ページ(範囲)989-996
ページ数8
ジャーナルCancer chemotherapy and pharmacology
76
発行部数5
DOI
出版物ステータス出版済み - 11 1 2015

Fingerprint

Chemokine CCL2
Biomarkers
Acute Kidney Injury
Cisplatin
Lipocalins
Lung Neoplasms
Gelatinases
Kidney
Hexosaminidases
Molecules
Wounds and Injuries
Creatinine
ROC Curve
Area Under Curve
Chemotherapy
Urine
Drug Therapy
Lipocalin-2
Proteins
Serum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

これを引用

Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. / Shinke, Haruka; Masuda, Satohiro; Togashi, Yousuke; Ikemi, Yasuaki; Ozawa, Aiko; Sato, Tomoko; Kim, Young Hak; Mishima, Michiaki; Ichimura, Takaharu; Bonventre, Joseph V.; Matsubara, Kazuo.

:: Cancer chemotherapy and pharmacology, 巻 76, 番号 5, 01.11.2015, p. 989-996.

研究成果: ジャーナルへの寄稿記事

Shinke, H, Masuda, S, Togashi, Y, Ikemi, Y, Ozawa, A, Sato, T, Kim, YH, Mishima, M, Ichimura, T, Bonventre, JV & Matsubara, K 2015, 'Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients', Cancer chemotherapy and pharmacology, 巻. 76, 番号 5, pp. 989-996. https://doi.org/10.1007/s00280-015-2880-y
Shinke, Haruka ; Masuda, Satohiro ; Togashi, Yousuke ; Ikemi, Yasuaki ; Ozawa, Aiko ; Sato, Tomoko ; Kim, Young Hak ; Mishima, Michiaki ; Ichimura, Takaharu ; Bonventre, Joseph V. ; Matsubara, Kazuo. / Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. :: Cancer chemotherapy and pharmacology. 2015 ; 巻 76, 番号 5. pp. 989-996.
@article{6163ea921af4443ba8d0f1d8128a0bf5,
title = "Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients",
abstract = "Purpose: Acute kidney injury (AKI) is a common and serious adverse effect of cisplatin-based chemotherapy. However, traditional markers of kidney function, such as serum creatinine, are suboptimal, because they are not sensitive measures of proximal tubular injury. We aimed to determine whether the new urinary biomarkers such as kidney injury molecule-1 (KIM-1), monocyte chemotactic protein-1 (MCP-1), and neutrophil gelatinase-associated lipocalin (NGAL) could detect cisplatin-induced AKI in lung cancer patients in comparison with the conventional urinary proteins such as N-acetyl-β-d-glucosaminidase (NAG) and β2-microglobulin. Methods: We measured KIM-1, MCP-1, NGAL, NAG, and β2-microglobulin concentrations in urine samples from 11 lung cancer patients, which were collected the day before cisplatin administration and on days 3, 7, and 14. Subsequently, we evaluated these biomarkers by comparing their concentrations in 30 AKI positive (+) and 12 AKI negative (-) samples and performing receiver operating characteristic (ROC) curve analyses. Results: The urinary levels normalized with urine creatinine of KIM-1 and MCP-1, but not NGAL, NAG, and β2-microglobulin in AKI (+) samples were significantly higher than those in AKI (-) samples. In addition, ROC curve analyses revealed that KIM-1 and MCP-1, but not NGAL, could detect AKI with high accuracy (area under the curve [AUC] = 0.858, 0.850, and 0.608, respectively). The combination of KIM-1 and MCP-1 outperformed either biomarker alone (AUC = 0.871). Conclusions: Urinary KIM-1 and MCP-1, either alone or in combination, may represent biomarkers of cisplatin-induced AKI in lung cancer patients.",
author = "Haruka Shinke and Satohiro Masuda and Yousuke Togashi and Yasuaki Ikemi and Aiko Ozawa and Tomoko Sato and Kim, {Young Hak} and Michiaki Mishima and Takaharu Ichimura and Bonventre, {Joseph V.} and Kazuo Matsubara",
year = "2015",
month = "11",
day = "1",
doi = "10.1007/s00280-015-2880-y",
language = "English",
volume = "76",
pages = "989--996",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients

AU - Shinke, Haruka

AU - Masuda, Satohiro

AU - Togashi, Yousuke

AU - Ikemi, Yasuaki

AU - Ozawa, Aiko

AU - Sato, Tomoko

AU - Kim, Young Hak

AU - Mishima, Michiaki

AU - Ichimura, Takaharu

AU - Bonventre, Joseph V.

AU - Matsubara, Kazuo

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Purpose: Acute kidney injury (AKI) is a common and serious adverse effect of cisplatin-based chemotherapy. However, traditional markers of kidney function, such as serum creatinine, are suboptimal, because they are not sensitive measures of proximal tubular injury. We aimed to determine whether the new urinary biomarkers such as kidney injury molecule-1 (KIM-1), monocyte chemotactic protein-1 (MCP-1), and neutrophil gelatinase-associated lipocalin (NGAL) could detect cisplatin-induced AKI in lung cancer patients in comparison with the conventional urinary proteins such as N-acetyl-β-d-glucosaminidase (NAG) and β2-microglobulin. Methods: We measured KIM-1, MCP-1, NGAL, NAG, and β2-microglobulin concentrations in urine samples from 11 lung cancer patients, which were collected the day before cisplatin administration and on days 3, 7, and 14. Subsequently, we evaluated these biomarkers by comparing their concentrations in 30 AKI positive (+) and 12 AKI negative (-) samples and performing receiver operating characteristic (ROC) curve analyses. Results: The urinary levels normalized with urine creatinine of KIM-1 and MCP-1, but not NGAL, NAG, and β2-microglobulin in AKI (+) samples were significantly higher than those in AKI (-) samples. In addition, ROC curve analyses revealed that KIM-1 and MCP-1, but not NGAL, could detect AKI with high accuracy (area under the curve [AUC] = 0.858, 0.850, and 0.608, respectively). The combination of KIM-1 and MCP-1 outperformed either biomarker alone (AUC = 0.871). Conclusions: Urinary KIM-1 and MCP-1, either alone or in combination, may represent biomarkers of cisplatin-induced AKI in lung cancer patients.

AB - Purpose: Acute kidney injury (AKI) is a common and serious adverse effect of cisplatin-based chemotherapy. However, traditional markers of kidney function, such as serum creatinine, are suboptimal, because they are not sensitive measures of proximal tubular injury. We aimed to determine whether the new urinary biomarkers such as kidney injury molecule-1 (KIM-1), monocyte chemotactic protein-1 (MCP-1), and neutrophil gelatinase-associated lipocalin (NGAL) could detect cisplatin-induced AKI in lung cancer patients in comparison with the conventional urinary proteins such as N-acetyl-β-d-glucosaminidase (NAG) and β2-microglobulin. Methods: We measured KIM-1, MCP-1, NGAL, NAG, and β2-microglobulin concentrations in urine samples from 11 lung cancer patients, which were collected the day before cisplatin administration and on days 3, 7, and 14. Subsequently, we evaluated these biomarkers by comparing their concentrations in 30 AKI positive (+) and 12 AKI negative (-) samples and performing receiver operating characteristic (ROC) curve analyses. Results: The urinary levels normalized with urine creatinine of KIM-1 and MCP-1, but not NGAL, NAG, and β2-microglobulin in AKI (+) samples were significantly higher than those in AKI (-) samples. In addition, ROC curve analyses revealed that KIM-1 and MCP-1, but not NGAL, could detect AKI with high accuracy (area under the curve [AUC] = 0.858, 0.850, and 0.608, respectively). The combination of KIM-1 and MCP-1 outperformed either biomarker alone (AUC = 0.871). Conclusions: Urinary KIM-1 and MCP-1, either alone or in combination, may represent biomarkers of cisplatin-induced AKI in lung cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84944715563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944715563&partnerID=8YFLogxK

U2 - 10.1007/s00280-015-2880-y

DO - 10.1007/s00280-015-2880-y

M3 - Article

C2 - 26407820

AN - SCOPUS:84944715563

VL - 76

SP - 989

EP - 996

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -